Selective neurodegeneration, neuropathology and symptom profiles in huntington's disease

Advances in Experimental Medicine and Biology

Volumn 769, Issue , 2012, Pages 141-152

  Waldvogel, Henry J ^a   Thu, Doris ^b   Hogg, Virginia ^a   Tippett, Lynette ^a   Faull, Richard L M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; GUANINE; HUNTINGTIN; POLYGLUTAMINE;

ANTERIOR CINGULATE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN DEGENERATION; CAG REPEAT; COGNITIVE DEFECT; CORPUS STRIATUM; DEMENTIA; DISEASE COURSE; EXON; GABAERGIC SYSTEM; GENE; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; HUNTINGTON GENE; INVOLUNTARY MOVEMENT; IT15 GENE; MOOD DISORDER; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PERSONALITY DISORDER; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; SYMPTOM; SYMPTOMATOLOGY; CELL LOSS; GENETIC VARIABILITY; HD GENE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS;

EID: 84934434205     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5434-2_9     Document Type: Article

References (75)

1. Illarioshkin SN, Igarashi S, Onodera O et al. Trinucleotide repeat length and rate ofprogression of Huntington's disease. Ann Neurol 1994; 36(4):630-635.
2. Sharp AH, Ross CA. Neurobiology of Huntington's disease. Neurobiol Dis 1996; 3(1):3-15.
3. Andrew SE, Goldberg YP, Kremer B et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993; 4(4):398-403.
4. Claes S, Van Zand K, Legius E et al. Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch Neurol 1995; 52(8):749-753.
5. Brandt J, Butters N. The neuropsychology of Huntington's disease. TINS 1986:118-120.
6. Folstein SE. Huntington's Disease: A Disorder of Families. Baltimore: John's Hopkins University Press; 1989.
7. Myers RH, Sax DS, Koroshetz WJ et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991; 48(8):800-804.
8. Thompson JC, Snowden JS, Craufurd D et al. Behavior in Huntington's disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci 2002; 14(1):37-43.
9. Zappacosta B, Monza D, Meoni C et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol 1996; 53(6):493-497.
10. Georgiou N, Bradshaw JL, Chiu E et al. Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov Disord 1999; 14(2):320-325.
11. Wexler NS, Lorimer J, Porter J et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. PNAS 2004; 101(10):3498-3503.
12. MacMillan JC, Snell RG, Tyler A et al. Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet 1993; 342(8877):954-958.
13. Telenius H, Kremer B, Goldberg YP et al. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat Genet 1994; 6(4):409-414.
14. Witjes-Ane MN, Zwinderman AH, Tibben A et al. Behavioural complaints in participants who underwent predictive testing for Huntington's disease. J Med Genet 2002; 39(11):857-862.
15. Di Maio L, Squitieri F, Napolitano G et al. Onset symptoms in 510 patients with Huntington's disease. J Med Genet 1993; 30(4):289-292.
16. Vonsattel JP, Myers RH, Stevens TJ et al. Neuropathological classification of Huntington's disease. J Neuropath Exp Neurol 1985; 44:559-577.
17. Vonsattel JPG, Difiglia M. Huntington-disease. JNeuropath and Exp Neurol 1998; 57(5):369-384.
18. Albin RL, Makowiec RL, Hollingsworth ZR et al. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 1992; 46:35-48.
19. Deng YP, Albin RL, Penney JB et al. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistocaahemical study. J Chem Neuroanat 2004; 27(3):143-164.
20. Faull RL, Waldvogel HJ, Nicholson LF et al. The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. Prog Brain Res 1993; 99:105-123.
21. Glass M, Dragunow M, Faull RLM. The pattern ofneurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97(3):505-519.
22. Glass M, Faull RL, Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 1993; 56(3):523-527.
23. Reiner A, Albin RL, Anderson KD et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988; 85(15):5733-5737.
24. Ferrante RJ, Kowall NW, Beal MF et al. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 1987; 46(1):12-27.
25. Vonsattel JP, Ge P, Kelly L. Huntington's disease. In: Esiri M, Morris JH, editors. The Neuropathology of Dementia. Cambridge: Cambridge University Press UK; 1997:219-240.
26. Allen KL, Waldvogel HJ, Glass M et al. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009; 37(4):266-281.
27. Graybiel AM, Ragsdale CW Jr. Histochemically distinct compartments in the striatum of human, monkeys and cat demonstrated by acetylthiocholinesterase staining. Proc Nat Acad Sci USA 1978; 75(11):5723-5726.
28. Holt DJ, Graybiel AM, Saper CB. Neurochemical architecture of the human striatum. J Comp Neurol 1997; 384:1-25.
29. Waldvogel HJ, Faull RLM. Compartmentalization of parvalbumin immunoreactivity in the human striatum. Brain Res 1993; 610:311-316.
30. Eblen F, Graybiel AM. Highly restricted origin of prefrontal cortical inputs to striosomes in the macaque monkey. J Neurosci 1995; 15(9):5999-6013.
31. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. TINS 1992; 15:133-138.
32. SakaE, Goodrich C, Harlan P et al. Repetitive behaviors in monkeys are linked to specific striatal activation patterns. J Neurosci 2004; 24(34):7557-7565.
33. White NM, Hiroi N. Preferential localization of self-stimulation sites in striosomes/patches in the rat striatum. Proc Natl Acad Sci USA 1998; 95(11):6486-6491.
34. Hedreen JC, Folstein SE. Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol Exp Neurol 1995; 54(1):105-120.
35. Morton AJ, Nicholson LF, Faull RL. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease. Neuroscience 1993; 53(1):159-168.
36. Seto-Ohshima A, Emson PC, Lawson E et al. Loss of matrix calcium-binding protein-containing neurons in Huntington's disease. Lancet 1988; 1234:1252-1254.
37. Olsen JM, Penney JB, Shoulson I et al. Inhomogeneities of striatal receptor binding in Huntington's disease. Neurology 1986; 36:342.
38. Augood SJ, Faull RL, Love DR et al. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 1996; 72(4):1023-1036.
39. Tippett LJ, Waldvogel HJ, Thomas SJ et al. Striosomes and mood dysfunction in Huntington's disease. Brain 2007; 130(Pt 1):206-221.
40. Alexopoulos GS, Gunning-Dixon FM, Latoussakis V et al. Anterior cingulate dysfunction in geriatric depression. Int J Geriatr Psychiatry 2008; 23(4):347-355.
41. Davidson RJ, Pizzagalli D, Nitschke JB et al. Depression: perspectives from affective neuroscience. Annu Rev Psychol 2002; 53:545-574.
42. Ebert D, Ebmeier KP. The role ofthe cingulate gyrus in depression: from functional anatomy to neurochemistry. Biol Psychiatry 1996; 39(12):1044-1050.
43. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002; 125(Pt 7):1428-1449.
44. Konarski JZ, McIntyre RS, Kennedy SH et al. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord 2008; 10(1):1-37.
45. Thu DC, Oorschot DE, Tippett LJ et al. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010; 133(Pt 4):1094-1110.
46. Cudkowicz M, Kowall NW. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann Neurol 1990; 27:200-204.
47. Hedreen JC, Peyser CE, Folstein SE et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 1991; 133(2):257-261.
48. Heinsen H, Strik M, Bauer M et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 1994; 88(4):320-333.
49. Macdonald V, Halliday G. Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol Dis 2002; 10(3):378-386.
50. Macdonald V, Halliday GM, Trent RJ et al. Significant lossof pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathol Appl Neurobiol 1997; 23(6):492-495.
51. Selemon LD, Rajkowska G, Goldman-Rakic PS. Evidence for progression in frontal cortical pathology in late-stage Huntington's disease. J Comp Neurol 2004; 468(2):190-204.
52. Rosas HD, Feigin AS, Hersch SM. Using advances in neuroimaging to detect, understand and monitor disease progression in Huntington's disease. NeuroRx 2004; 1(2):263-272.
53. Rosas HD, Hevelone ND, Zaleta AK et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005; 65(5):745-747.
54. Rosas HD, Koroshetz WJ, Chen YI et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003; 60(10):1615-1620.
55. Rosas HD, Liu AK, Hersch S et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002; 58(5):695-701.
56. Rosas HD, Salat DH, Lee SY et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008; 131(Pt 4):1057-1068.
57. Hodges A, Strand AD, Aragaki AK et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006; 15(6):965-977.
58. Luthi-Carter R, Strand A, Peters NL et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000; 9(9):1259-1271.
59. Cattaneo E, Rigamonti D, Goffredo D et al. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001; 24(3):182-188.
60. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 2000; 23(9):387-392.
61. Morton AJ, Faull RL, Edwardson JM. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res Bull 2001; 56(2):111-117.
62. Petersen A, Mani K, Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp Neurol 1999; 157(1):1-18.
63. Rosas HD, Salat DH, Lee SY et al. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci 2008; 1147:196-205.
64. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007; 81(5-6):294-330.
65. Cepeda C, Wu N, Andre VM et al. The corticostriatal pathway in Huntington's disease. Prog Neurobiol 2007; 81(5-6):253-271.
66. Strand AD, Baquet ZC, Aragaki AK et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 2007; 27(43):11758-11768.
67. Molyneaux BJ, Arlotta P, Menezes JR et al. Neuronal subtype specification in the cerebral cortex. Nat Rev Neurosci 2007; 8(6):427-437.
68. Cummings DM, Andre VM, Uzgil BO et al. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 2009; 29(33):10371-10386.
69. Andre VM, Cepeda C, Venegas A et al. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J Neurophysiol 2006; 95(4):2108-2119.
70. Laforet GA, Sapp E, Chase K et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001; 21(23):9112-9123.
71. Sapp E, Schwarz C, Chase K et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997; 42(4):604-612.
72. Gu X, Andre VM, Cepeda C et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener 2007; 2:8.
73. Gu X, Li C, Wei W et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005; 46(3):433-444.
74. Spampanato J, Gu X, Yang XW et al. Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 2008; 157(3):606-620.
75. Van Roon-Mom WM, Hogg VM, Tippett LJ et al. Aggregate distribution in frontal and motor cortex in Huntington's disease brain. Neuroreport 2006; 17(6):667-670.